# NanoViricides Inc. (NNVC)

Source: https://www.quantisnow.com/company/NNVC
Generated: 2026-11-09T02:30:32.607Z

- Ticker: NNVC
- Exchange: AMEX
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001379006
- Website: nanoviricides.com

## About

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

## Latest NNVC news and filings

- 2026-10-27 13:15 UTC [Market Insight] [As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides](https://www.quantisnow.com/insight/as-ebola-spreads-to-multiple-countries-the-importance-of-nv-387-6758819)
- 2026-10-21 14:15 UTC [SEC Form 424B5] [SEC Form 424B5 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nanoviricides-inc-6753227)
- 2026-10-20 12:45 UTC [Market Insight] [NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials](https://www.quantisnow.com/insight/nanoviricides-revolutionary-broad-spectrum-drug-candidate-nv-387-has-successfully-demonstrated-excellent-6751664)
- 2026-10-13 12:45 UTC [Market Insight] [Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides](https://www.quantisnow.com/insight/phase-ii-clinical-trial-of-nv-387-oral-gummies-as-treatment-6744421)
- 2026-10-08 15:28 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-nanoviricides-inc-6741482)
- 2026-10-06 12:45 UTC [Market Insight] [NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026](https://www.quantisnow.com/insight/nanoviricides-presenting-at-nibas-153rd-investment-conference-in-fort-lauderdale-6738397)
- 2026-10-05 12:45 UTC [Market Insight] [NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives](https://www.quantisnow.com/insight/nanoviricides-provides-additional-details-on-the-phase-ii-clinical-trial-6736162)
- 2026-09-29 20:30 UTC [SEC Form 8-K] [NanoViricides Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/nanoviricides-inc-filed-sec-form-8-k-leadership-update-6729353)
- 2026-09-29 12:45 UTC [Market Insight] [NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials](https://www.quantisnow.com/insight/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-6728702)
- 2026-09-28 20:30 UTC [SEC Form 10-K] [SEC Form 10-K filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-nanoviricides-inc-6727851)
- 2026-09-28 12:45 UTC [Market Insight] [Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides](https://www.quantisnow.com/insight/clinical-trial-of-the-oral-drug-nv-387-to-treat-ebola-6727280)
- 2026-09-23 12:30 UTC [Market Insight] [Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides](https://www.quantisnow.com/insight/phase-ii-clinical-trial-of-nv-387-as-a-treatment-for-6723741)
- 2026-09-15 13:25 UTC [Market Insight] [Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides](https://www.quantisnow.com/insight/clinical-trial-of-the-oral-drug-nv-387-to-treat-ebola-6715708)
- 2026-09-15 13:00 UTC [A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat](https://www.quantisnow.com/insight/a-57-billion-antiviral-market-is-taking-shape-as-the-6715599)
- 2026-09-08 12:30 UTC [Market Insight] [Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo](https://www.quantisnow.com/insight/clinical-trial-for-an-oral-drug-to-treat-ebola-is-6707659)
- 2026-09-03 01:34 UTC [SEC Form 424B3] [SEC Form 424B3 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-nanoviricides-inc-6704056)
- 2026-09-01 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nanoviricides-inc-6700362)
- 2026-08-31 12:30 UTC [Market Insight] [While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles](https://www.quantisnow.com/insight/while-measles-cases-continue-to-increase-in-the-usa-and-6699250)
- 2026-08-21 20:30 UTC [SEC Form S-3] [SEC Form S-3 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-nanoviricides-inc-6691490)
- 2026-08-18 12:30 UTC [Market Insight] [The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon](https://www.quantisnow.com/insight/the-phase-ii-clinical-trial-of-nv-387-oral-gummies-as-6685996)
- 2026-08-10 12:30 UTC [Market Insight] [NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak](https://www.quantisnow.com/insight/nanoviricides-has-received-regulatory-approval-for-a-phase-ii-clinical-6672929)
- 2026-07-30 10:02 UTC [SEC Form 8-K] [NanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nanoviricides-inc-filed-sec-form-8-k-entry-into-a-material-6654641)
- 2026-07-28 12:30 UTC [Market Insight] [NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial](https://www.quantisnow.com/insight/nanoviricides-awaits-approval-from-dr-congo-regulatory-agency-for-a-6650836)
- 2026-07-27 10:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nanoviricides-inc-6648871)
- 2026-07-27 10:05 UTC [SEC Form 424B5] [SEC Form 424B5 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nanoviricides-inc-6648847)
- 2026-07-24 12:00 UTC [Market Insight] [NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering](https://www.quantisnow.com/insight/nanoviricides-announces-pricing-of-38-million-registered-direct-offering-6647918)
- 2026-07-22 12:30 UTC [Market Insight] [As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola](https://www.quantisnow.com/insight/as-ebola-death-toll-surpasses-930-within-two-months-nanoviricides-6644759)
- 2026-07-17 20:45 UTC [SEC Form 8-K] [NanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/nanoviricides-inc-filed-sec-form-8-k-entry-into-a-material-6641263)
- 2026-07-17 20:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-nanoviricides-inc-6641203)
- 2026-07-13 13:27 UTC [Market Insight] [As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo](https://www.quantisnow.com/insight/as-ebola-spreads-in-two-more-provinces-nanoviricides-has-received-6635066)
- 2026-07-08 12:30 UTC [Market Insight] [Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily](https://www.quantisnow.com/insight/research-analyst-report-on-nanoviricides-rates-company-outperform-separately-a-6630986)
- 2026-07-06 12:30 UTC [Market Insight] [As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo](https://www.quantisnow.com/insight/as-the-ebola-epidemic-spreads-nanoviricides-advances-towards-a-phase-6627406)
- 2026-07-01 20:30 UTC [SEC Form 424B3] [SEC Form 424B3 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-nanoviricides-inc-6623150)
- 2026-06-29 12:30 UTC [Market Insight] [US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher](https://www.quantisnow.com/insight/us-fda-has-granted-a-rare-pediatric-disease-drug-designation-6618391)
- 2026-06-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nanoviricides-inc-6618058)
- 2026-06-23 14:19 UTC [SEC Form DEL AM filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-del-am-filed-by-nanoviricides-inc-6612167)
- 2026-06-22 13:30 UTC [Market Insight] [NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo](https://www.quantisnow.com/insight/nanoviricides-has-shipped-nv-387-oral-gummies-drug-product-for-phase-6610340)
- 2026-06-16 23:31 UTC [SEC Form DEL AM filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-del-am-filed-by-nanoviricides-inc-6605702)
- 2026-06-16 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-nanoviricides-inc-6603731)
- 2026-06-15 20:30 UTC [SEC Form S-3] [SEC Form S-3 filed by NanoViricides Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-nanoviricides-inc-6602861)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NNVC
- Earnings history: https://www.quantisnow.com/earnings/NNVC
- Dividend history: https://www.quantisnow.com/dividends/NNVC
- Insider transactions: https://www.quantisnow.com/insiders/NNVC
- Options chain: https://www.quantisnow.com/options/NNVC
- SEC 8-K filings only: https://www.quantisnow.com/company/NNVC/8-k
- RSS and alerts for NNVC: https://www.quantisnow.com/docs/rss-feeds.md